Pancreatic Cancer Research

Clinical trialNAActive not recruiting

Feasibility of Molecular Biology in Pancreatic Cyst Tumors

Study of Feasibility and Diagnostic Profitability of Intra-cyst Fluid Molecular Biology Analysis in Pancreatic Cyst Tumors.

NCT03305146↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome
Ongoing
Phase
NA
Status
Active not recruiting
Study type
Interventional
Start
January 2017
Expected end
January 2027
Enrollment
93 participants
Sites
11
Primary outcomes
Comparison between gene mutations found into the pancreatic cystic tumor fluid to gene mutations found into tissue specimen
Sponsor
Other
Results posted
No
Last update
14 April 2022

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The main objective of the study is to compare the diagnostic accuracy of intra-cystic fluid DNA molecular analysis to standard diagnostics. The secondary objective of the study is to evaluate the feasibility of intra-cystic fluid DNA molecular analysis.

Detailed description public domain (ClinicalTrials.gov)

Multicenter study to determinate the feasibility of intra-cystic fluid DNA molecular analysis in patients with suspected cystic tumours of pancreas in whom EUS FNA is clinically indicated. Morphological criteria obtained by MRI and computerised tomography (tumor characterization (size, metastases presence, dilatation of bile ducts), etiologic diagnosis, serious symptoms), biological exams (biomarkers), cytological analysis will lead to a diagnosis and a treatment. The goal of this study is to compare this standard diagnostic modalities to diagnosis obtained by intra-cystic fluid DNA molecular analysis. Is the DNA molecular analysis improve the diagnosis accuracy.

Papers 8